anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a serial Chinese medicinal preparation for treating child common cold, a preparation process and a quality control method thereof. Preparations are characterized by being prepared from traditional Chinese medicines, namely indigowoad leaf, Chinese thorowax root, baical skullcap root, fineleaf schizonepeta herb, platycodon root and liquoric root as well as pharmaceutical excipients. The preparations have the effects of clearing away heat, relieving exterior syndromes, reducing inflammation and relieving cough, and are used for common cold and fever, headache and stuffed-up nose, cough and sneeze, and sore throat. Volatile oil from Chinese thorowax root is a material base of the 'defervescence' of the preparation, has the characteristic of quick defervescence, and is an active ingredient for treating exogenous fever of children; and the traditional preparation process is to adopt a way of spraying the volatile oil into the preparation, and the volatile oil is almost completely lost during the production and storage due to the low content of the volatile oil, so that the clinical therapeutic effect is seriously affected. In the preparation process, a beta-cyclodextrin inclusion technology is adopted for the inclusion of the volatile oil from Chinese thorowax root to ensure that a liquid medicine is solidified; and thus the loss of the volatile oil during the production and storage is reduced, and the stability of the medicine is improved and the clinical therapeutic effect of the medicine is ensured at the same time. In addition, the more perfect quality control method is used for ensuring the quality; meanwhile, the clinical medication formulation is also enriched, so that the clinical medication demand can be better met.
Knowledge is lacking on separation strategies that can best prepare calves to final separation from the dam in cow-calf contact (CCC) systems. This controlled trial compared the effects of 2 different methods to gradually reduce cows' access to their calf termed "debonding" on calf growth in a cow-driven CCC system. Initially, cows (Norwegian Red breed) had 24 h/d computer-controlled access to their calves. In the long debonding (LDB) treatment (n = 16), a gradual reduction of cows' access to their calves was initiated 28 d after calving over a total duration of 28 d; first to 12 h/d (14 d), and then to 6 h/d (14 d). In the short debonding (SDB) treatment (n = 14), reduction was initiated 45 d after calving over a total duration of 10 d; first to 12 h/d (5 d), and then to 6 h/d (5 d). From 6 h/d, access was finally reduced to 0 h/d for 4 d for both treatments, resulting in a study period of 60 d in total. Calves had ad libitum access to concentrate, hay and water throughout the study. Independent of treatment, ad libitum access to whole milk from an automatic feeder was granted once cow access was reduced. Cows and calves had the possibility for fence line contact at all times. The primary outcome variable calf weight gain was registered biweekly. Calf ADG was analyzed with a linear mixed model. The ADG was similar across treatments during 24 h/d access (1.04 ± 0.07 kg). Debonding treatment affected calf growth differently with each gradual reduction in cow access (12 h/d, 6 h/d and 0 h/d); however, no main effect of treatment was detected. The SDB calves had a pattern of increased ADG with the first reduction in access (+0.39 ± 0.18kg), followed by significant growth checks as access was reduced further to 6 h/d and 0 h/d (-0.41 ± 0.20 kg and -1.15 ± 0.31 kg, respectively). The LDB calves only showed significant weight checks at the final reduction in access (0 h/d access), yet at a lower degree (-0.46 ± 0.21 kg) than SDB calves. As expected, ADG was negatively associated with health events but positively associated with intake of concentrate and supplemental milk. Collectively, the results from the present study might point toward a long adaptation to separation which is initiated at a younger age being more favorable for calf performance.
BACKGROUND: Ductal carcinoma in situ (DCIS) of the breast is an early stage of breast cancer, and preventing its progression to invasive ductal carcinoma (IDC) is crucial for the early detection and treatment of breast cancer. Although single-cell transcriptome analysis technology has been widely used in breast cancer research, the biological mechanisms underlying the transition from DCIS to IDC remain poorly understood.
RESULTS: We identified eight cell types through cell annotation, finding significant differences in T cell proportions between DCIS and IDC. Using this as a basis, we performed pseudotime analysis on T cell subpopulations, revealing that differentially expressed genes primarily regulate immune cell migration and modulation. By intersecting WGCNA results of T cells highly correlated with the subtypes and the differentially expressed genes, we identified six key genes: FGFBP2, GNLY, KLRD1, TYROBP, PRF1, and NKG7. Excluding PRF1, the other five genes were significantly associated with overall survival in breast cancer, highlighting their potential as prognostic biomarkers.
CONCLUSIONS: We identified immune cells that may play a role in the progression from DCIS to IDC and uncovered five key genes that can serve as prognostic markers for breast cancer. These findings provide insights into the mechanisms underlying the transition from DCIS to IDC, offering valuable perspectives for future research. Additionally, our results contribute to a better understanding of the biological processes involved in breast cancer progression.
Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences, in particular for at-risk populations such as pregnant women and young infants. Pregnancy malaria is associated with low birth weight (LBW), maternal anemia, and gestational hypertension; both inflammation and the fetal response to infection may contribute to these poor outcomes. Placental malaria (PM) is caused by P. falciparum-infected erythrocytes that bind to the placental receptor chondroitin sulfate A (CSA) and sequester in the placenta, where they cause disease and may lead to death for the mother and her offspring. Women become resistant to PM as they acquire antibodies that target surface proteins of placental parasites. In areas of stable transmission, acute severe malaria syndromes are limited to children under 5 years of age. The pathogenesis of severe malaria remains poorly understood, although some evidence suggests that parasites causing severe malaria may express distinct antigens on the surface of infected erythrocytes. Thus, vaccines to prevent malarial disease may need to target distinct antigens in order to protect pregnant women or young children.

The primary hypothesis in this study is that the burden of P. falciparum infection around Maferinyah, Guinea is sufficient to support future studies of malaria pathogenesis and immunity. We plan to enroll 1050 pregnant women and 1050 infants into a cross sectional study that will be conducted in Maferinyah and neighboring areas, Guinea. Women presenting for routine antenatal visits and older infants presenting for routine healthy visits (e.g, vaccinations, vitamins) at the health center in Maf(SqrRoot)(Registered Trademark)rinyah will be offered enrollment. Samples collected from the women and infants will be examined for evidence of infection by Pla smodium and other parasitic diseases in order to assess prevalence in these important reservoir populations. For our primary outcome, we will determine the prevalence of P. falciparum infection in these two key demographic groups, including their annual and seasonal variations, as these data will form the basis to design future natural history or interventional studies at this site. For our secondary outcomes, we will determine the prevalence of other parasitic infections based on multiplexed serologic assessments of blood samples.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease where the body loses tolerance to its own antigens, particularly nuclear antigens. Abnormal responses from T and B cells lead to the production of autoantibodies and the formation of immune complexes in tissues, triggering complement activation, inflammation, and irreversible organ damage. SLE can affect any part of the body, resulting in diverse clinical symptoms. One rare manifestation of SLE is lupus mesenteric vasculitis (LMV), which presents with vague symptoms, abnormal laboratory findings, and specific imaging features. LMV, although uncommon, can progress to severe complications such as bowel perforation, haemorrhage, and even mortality. Here, we report a case of LMV with the involvement of multiple organ systems (including mucocutaneous, musculoskeletal, serosal cavities, and haematological systems), presenting initially with life-threatening intractable gastrointestinal bleeding, and complicated by severe pulmonary infection. By sharing this case, we aim to enhance clinicians' confidence in managing critical SLE cases and raise awareness about disease surveillance.
The systems and methods can accurately and efficiently determine boundary conditions for an arterial segment and thereby efficiently determine hemodynamic information for that segment. The method may include receiving medical image data of a patient. The method may further include generating a geometrical representation of the one or more arterial segments from the medical image data. The method may further include determining boundaries and geometry data for each arterial segment. The method may further include determining boundary conditions for the inflow boundary and each outflow boundary. The boundary conditions for each outflow boundary may be determined using an outflow distribution parameter. The outflow distribution parameter may be determined using the geometry data for one or more of the one or more outflow boundaries, stored hemodynamic data, or a combination thereof. The method may further include determining flow field for each arterial segment and determining hemodynamic information.
Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Early enteral nutrition (EN) initiation is recommended for intensive care unit (ICU) patients; however, the optimal rate of EN advancement remains unclear. We aimed to assess the association between EN advancement and in-hospital mortality, as well as length of hospital stay.
METHODS: We performed a retrospective cohort study on 341 critically ill adults receiving EN between January 2021 and December 2023. The exposure of interest was rapid EN advancement, defined as an EN change exceeding the median value calculated between the first and seventh days after EN initiation. The comparator group included patients without rapid EN advancement. Factors related to in-hospital mortality and length of hospital stay were assessed using multivariable logistic and linear regression analyses. Subgroup analyses were performed for EN initiation within 48 h of ICU admission.
RESULTS: Rapid EN advancement reduced in-hospital mortality (adjusted odds ratio [OR] = 0.64, 95% CI 0.38-1.07, P = 0.092), although this was not statistically significant. However, rapid EN advancement significantly shortened hospital stay by 25 days (95% CI -25 to -9.2, P = 0.002). In the early EN initiation subgroup, rapid EN advancement significantly reduced in-hospital mortality (adjusted OR = 0.42, P = 0.039) and shortened hospital stay by 48 days (95% CI -77 to -19, P = 0.001).
CONCLUSION: Rapid EN advancement reduced in-hospital mortality and length of hospital stay in critically ill patients, especially with early EN initiation. These findings could inform clinical practices that enhance timely and adequate nutrition therapy in ICUs. Further randomized controlled trials can help establish clinical guidelines.
BACKGROUND: Myocardial injury after noncardiac surgery (MINS) is associated with 30-day mortality in heterogeneous surgical populations but is barely described after acute high-risk abdominal surgery. The impact of dynamic changes has not previously been investigated. The objectives were to determine the incidence of MINS in this population, the association between mortality and MINS, and whether plasma troponin I (TnI) dynamics have any impact on mortality.
METHODS: A prospective cohort study of 341 patients undergoing acute high-risk gastrointestinal surgery was conducted. Plasma TnI was measured at the first four postoperative days. MINS was defined as any increased TnI level >59 ng/L. TnI dynamic required either two succeeding measurements of TnI >59 ng/L with a >20% increase/fall or one measurement of TnI >59 ng/L with a succeeding measurement of TnI <59 ng/L with a >50% decrease. Adjusted mortality rates were calculated using inverse probability of treatment weighting and competing risk analyses.
RESULTS: The incidence of MINS was 23.8% and dynamic TnI changes occurred in 15.6% of the patients. The unadjusted 30-day and 1-year mortality were 19.8% and 35.9% in patients with MINS, compared with 2.7% and 11.6%, respectively, in patients without MINS (p < 0.001). After adjusting, the differences remained significant. There was no difference in mortality between patients with or without dynamic changes in TnI level.
CONCLUSION: MINS occurred frequently and was associated with increased mortality. TnI monitoring might help identify patients with increased risk of mortality and improve care. Research on preventive measures and treatments is warranted.
TRIAL REGISTRATION NUMBER AND AGENCY: ClinicalTrials.gov Identifier: NCT05933837, retrospective registered.
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Losartan Potassium and Hydrochlorothiazide Tablets for a condition for which it was not prescribed. Do not give Losartan Potassium and Hydrochlorothiazide Tablets to other people, even if they have the same symptoms that you have. It may harm them. 

This leaflet summarizes the most important information about Losartan Potassium and Hydrochlorothiazide Tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information that is written for health professionals.
Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
This study is a phase I multicenter, single arm, open, dose increasing, single treatment clinical study. This study plans to recruit a total of about 10-16 adult patients with CD19 positive recurrent or refractory DLBCL for a single autologous car-t cell therapy. There were three dose groups in the study, and one patient in the first dose group, If there is no dose limiting toxicity (DLT), it can be increased to the second dose group, otherwise it will continue to be included in the group according to the "3 + 3" method; the follow-up dose group is designed according to the traditional "3 + 3" design, that is, three subjects will be included in a dose group first, if there is no dose limiting toxicity in the three patients in the dose group (DLT), after completing the DLT observation period, it can be increased to the next higher dose; if one of the three patients in the dose group has DLT, it is necessary to continue to join the group of three patients in the dose group for DLT observation. The highest dose level of DLT in less than or equal to one of the six patients finally confirmed will be defined as MTD. By observing the adverse events after cell therapy, the patients will be evaluated Evaluate the safety of car-t treatment; Evaluate the effectiveness of car-t treatment compared with the results or historical data of the patient's own previous standard treatment regimen. Blood and bone marrow were collected before and 12 months after cell infusion to detect the number and activity of car-t cells, Evaluate the pharmacokinetics (PK) of car-t cells. During the study, the blood samples used for the production of car-t cells will be transported to Shenzhen xiankangda Life Sciences Co., Ltd. (sponsor). After the production of car-t cells is completed, the car-t cells will be sent to the research unit so that the researchers can infuse them to the corresponding subjects.
PAXIL CR is indicated for the treatment of PMDD.

The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY: Clinical Trials).

The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant.

The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
The invention belongs to the field of traditional Chinese medicines, and relates to application of a traditional Chinese medicine composition in treating parkinsonism and a preparation method thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 30-120 parts of radix phyllostachys praecox; 1-10 parts of raw arisaema tuber; 1-10 parts of prepared rhizoma arisaematis; 1-60 parts of cicada slough; 1-60 parts of dark plum; 1-10 parts of notopterygium root; 1-10 parts of centipede; 1-10 parts of magnolia officinalis; 1-10 parts of dried ginger. Formula 2. 30-120 parts of radix Phyllostachydis Henonis; 1-10 parts of prepared rhizoma arisaematis; 1-60 parts of cicada slough; 1-60 parts of dark plum; 1-10 parts of notopterygium root; 1-10 parts of centipede; 1-10 parts of magnolia officinalis; 1-10 parts of dried ginger. Formula 3. 30-120 parts of radix Phyllostachydis Henonis; 1-10 parts of arisaema cum bile; 1-60 parts of cicada slough; 1-60 parts of dark plum; 1-10 parts of notopterygium root; 1-10 parts of centipede; 1-10 parts of magnolia officinalis; 1-10 parts of dried ginger. The traditional Chinese medicine composition has a good treatment effect on parkinsonism model mice, and the effect can be compared with that of dopa hydrazine tablet, and is expected to be further developed into a clinical medicament for treating parkinsonism.
Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
PROBLEM TO BE SOLVED: To a plaster having high skin permeation performance of a medicine and low irritation to skin and safety to organisms by forming a tacky agent layer containing a tacky agent, a medicine and a specific absorption promoting agent onto one surface of a support. SOLUTION: This plaster is obtained by forming a tacky agent layer containing an acrylic tacky agent, granite porphyry, a polyhydric alcohol (e.g. propylene glycol) and a medicine onto one surface of a support or forming a tacky agent layer containing an acrylic tacky agent, granite porphyry, a water-absorbing polymer (e.g. crystalline cellulose) and a medicine onto one surface of the support or forming a tacky agent containing an acrylic emulsion type tacky agent, granite porphyry and a medicine onto one surface of the support or forming a tacky agent layer containing a water-soluble polymer (e.g. polyvinyl alcohol), granite porphyry and a medicine on one surface of the support. The medicine includes e.g. antipyretic analgesics, an antihistaminic agent or an antiulcerous agent.
Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
BACKGROUND: Bilateral diaphragmatic dysfunction can lead to dyspnea and recurrent respiratory failure. In rare cases, it may result from high cervical spinal cord ischemia (SCI) due to anterior spinal artery syndrome (ASAS). We present a case of a patient experiencing persistent isolated diaphragmatic paralysis after SCI at level C3/C4 following thoracic endovascular aortic repair (TEVAR) for Kommerell's diverticulum. This is, to our knowledge, the first documented instance of a patient fully recovering from tetraplegia due to SCI while still exhibiting ongoing bilateral diaphragmatic paralysis.
CASE PRESENTATION: The patient, a 67-year-old male, presented to the Vascular Surgery Department for surgical treatment of symptomatic Kommerell's diverticulum in an aberrant right subclavian artery. After successful surgery in two stages, the patient presented with respiratory insufficiency and flaccid tetraparesis consistent with anterior spinal artery syndrome with maintained sensibility of all extremities. A computerized tomography scan (CT) revealed a high-grade origin stenosis of the left vertebral artery, which was treated by angioplasty and balloon-expandable stenting. Consecutively, the tetraparesis immediately resolved, but weaning remained unsuccessful requiring tracheostomy. Abdominal ultrasound revealed a residual bilateral diaphragmatic paralysis. A repeated magnetic resonance imaging (MRI) 14 days after vertebral artery angioplasty confirmed SCI at level C3/C4. The patient was transferred to a pulmonary clinic with weaning center for further recovery.
CONCLUSIONS: This novel case highlights the need to consider diaphragmatic paralysis due to SCI as a cause of respiratory failure in patients following aortic surgery. Diaphragmatic paralysis may remain as an isolated residual in these patients.